Our study demonstrates the successful design of potent GRPR radioantagonists featuring non-linear, conformationally restricted structures, and holds strong potential to significantly expand the range of diagnostic and therapeutic radioligands available for PET imaging of prostate cancer. Here, GRPR is linked to prostate carcinoma.